Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Initiation of Phase II Trial with FDX104 in Chemotherapy Induced Rash
Rehovot, Israel, and Bridgewater, NJ –    October 6, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”, or “Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Closing of Initial Public Offering
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 23, 2014 (GLOBE NEWSWIRE) --    Foamix Pharmaceuticals Ltd. ( FOMX ), ("Foamix Pharmaceuticals" or "Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address
Toggle Summary Foamix Pharmaceuticals Ltd. Prices Initial Public Offering
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) --   Foamix Pharmaceuticals Ltd. ("Foamix Pharmaceuticals", or "Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in